November 9th webcast to include a review of third quarter 2023 financial results
EMERYVILLE, CA October 31, 2023—(BUSINESS WIRE)–OmniAb, Inc. (Nasdaq: OABI) announces the agenda for its virtual research and technology event to be held on Thursday, November 9th beginning at 11:00 a.m. ET. The two-hour event will include an update on the company’s technology offerings, a review of third-quarter financial results to be announced earlier that morning, and a question-and-answer session.
The agenda of the event is as follows:
Business Review and Updates – Matt Foer, CEO
Creating value for our partners – Todd Pettingill, Vice President, Business Development and Strategy
Introducing OmnidAb™ Technology – Bill Harriman, PhD, Senior Vice President, Antibody Discovery
Improving discovery with OmniDeep™ – Bob Chen, Ph.D., Senior Director, Discovery Systems
The Ion Channel Opportunity – Doug Craft, PhD, Senior Vice President, Ion Channels/Transporters
Financial Updates – Kurt Gustafsson, Chief Financial Officer
Interested parties are requested to pre-register by clicking here. The live and archived webcast, along with the speakers’ slides, will be available on the Investors section of OmniAb’s website.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. At the heart of the OmniAb platform is biological intelligence™ (BI) of our own transgenic animals, including the OmniRat®OmniChicken® and OmniMouse® which have been genetically engineered to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. OmniFlic® (transgenic rat) and OmniClic® (transgenic chicken) meets industry needs for bispecific antibody applications through a common light chain approach and OmniTaur™ has the unique structural features of cow antibodies for complex targets. We believe that OmniAb animals comprise the most diverse host systems available in the industry and are optimally utilized by computational antigen design and immunization methods coupled with high-throughput phenotypic screening of single B cells and extraction of sequencing datasets from next generation with custom algorithms to identify fully human antibodies with superior performance and development characteristics. These proprietary technologies are combined and leverage OmniDeep™, which is a set of in silico therapeutic discovery and optimization tools that are woven into OmniAb’s various technologies and capabilities. Additionally, an established core competency focused on ion channels and transporters further differentiates OmniAb’s technology and creates opportunities in many emerging target classes. OmniAb antibodies have been used in a variety of modalities, including bispecific antibodies, antibody-drug conjugates, and others.
The OmniAb suite of technologies spans from BI-driven repertoire generation to state-of-the-art antibody discovery and optimization, offering a highly efficient and adaptable end-to-end solution for the growing discovery needs of the global pharmaceutical industry.
For more information, please visit www.omniab.com.
Check out the source version on businesswire.com: https://www.businesswire.com/news/home/20231031545244/en/
Neha Singh, Ph.D
X (Twitter) @OmniAbTech